Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2017; 19:40-50.
07.12.2017Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
07.12.2017Lancet Oncol 2017; 19:40-50
Denkert Carsten, Engels Knut, Schneeweiss Andreas, Hartmann Arndt, Noske Aurelia, Fasching Peter A, Jackisch Christian, van Mackelenbergh Marion, Sinn Peter, Schem Christian, Hanusch Claus, Untch Michael, Kümmel Sherko, Pfitzner Berit M, Karn Thomas, von Minckwitz Gunter, Darb-Esfahani Silvia, Lederer Bianca, Heppner Barbara I, Weber Karsten E, Budczies Jan, Huober Jens, Klauschen Frederick, Furlanetto Jenny, Schmitt Wolfgang D, Blohmer Jens-Uwe, Loibl Sibylle
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott Z, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou Q, Olsen J, Hajduch M, Cvek B, Deshaies R, Vrobel I, Dzubak P, Mistrik M, Andersen K, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017; 552:194-199.
06.12.2017Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
06.12.2017Nature 2017; 552:194-199
Skrott Zdenek, Pouckova Pavla, Sedlacek Jindrich, Miklovicova Andrea, Kutt Anne, Li Jing, Mattova Jana, Driessen Christoph, Dou Q Ping, Olsen Jørgen, Hajduch Marian, Cvek Boris, Deshaies Raymond J, Vrobel Ivo, Dzubak Petr, Mistrik Martin, Andersen Klaus Kaae, Friis Søren, Majera Dusana, Gursky Jan, Ozdian Tomas, Bartkova Jirina, Turi Zsofia, Moudry Pavel, Kraus Marianne, Michalova Martina, Vaclavkova Jana, Bartek Jiri
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer
Fankhauser C, Moch H, Sulser T, Poyet C, Hermanns T, Rueschoff J, Rupp N, Omlin A, Gillessen Sommer S, Schüffler P, Wild P. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2017; 9:10284-10293.
04.12.2017Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer
04.12.2017Oncotarget 2017; 9:10284-10293
Fankhauser Christian D, Moch Holger, Sulser Tullio, Poyet Cédric, Hermanns Thomas, Rueschoff Jan H, Rupp Niels J, Omlin Aurelius, Gillessen Sommer Silke, Schüffler Peter J, Wild Peter J
The role of radiation therapy in the management of small cell lung cancer
Glatzer M, Schmid S, Radovic M, Früh M, Putora P. The role of radiation therapy in the management of small cell lung cancer. Breathe (Sheff) 2017; 13:e87-e94.
01.12.2017The role of radiation therapy in the management of small cell lung cancer
01.12.2017Breathe (Sheff) 2017; 13:e87-e94
Glatzer Markus, Schmid Sabine, Radovic Marco, Früh Martin, Putora Paul Martin
Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
Jörger M, Miller M, Baburina I, Jog S, Cline D, Courtney J, Hilger R, Jaehde U, Kraff S, Salamone S. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit 2017; 39:617-624.
01.12.2017Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
01.12.2017Ther Drug Monit 2017; 39:617-624
Jörger Markus, Miller M Craig, Baburina Irina, Jog Sonali, Cline Daniel J, Courtney Jodi B, Hilger Ralf A, Jaehde Ulrich, Kraff Stefanie, Salamone Salvatore J
Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey
Rothermundt C, Stacchiotti S, Sleijfer S, Miah A, Lindner L, Kollár A, Kasper B, Italiano A, Grünwald V, Blay J, Bauer S, Fischer G, Putora P. Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. Oncologist 2017
30.11.2017Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey
30.11.2017Oncologist 2017
Rothermundt Christian, Stacchiotti Silvia, Sleijfer Stefan, Miah Aisha, Lindner Lars H, Kollár Attila, Kasper Bernd, Italiano Antoine, Grünwald Viktor, Blay Jean-Yves, Bauer Sebastian, Fischer Galina, Putora Paul Martin
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
Villegas S, Denkert C, Mehta K, Müller V, Kümmel S, Engels K, Lederer B, Pfitzner B, Schem C, Furlanetto J, Marmé F, Weber K, Huober J, von Minckwitz G, Darb-Esfahani S, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187.
25.11.2017Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
25.11.2017Breast Cancer Res Treat 2017; 168:179-187
Villegas S L, Denkert C, Mehta K, Müller V, Kümmel S, Engels K, Lederer B, Pfitzner B M, Schem C, Furlanetto J, Marmé F, Weber K, Huober Jens, von Minckwitz G, Darb-Esfahani S, Loibl S
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
21.11.2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
21.11.2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka
Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
Bossi P, Licitra L, Canevari S, Locati L, Pilotti S, Perrone F, Marchesi E, Paoli A, Tonella L, Giannoccaro M, Sponghini A, Cossu Rocca M, Bergamini C, Siano M, De Cecco L. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Dis Markers 2017; 2017:6870614.
12.11.2017Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
12.11.2017Dis Markers 2017; 2017:6870614
Bossi Paolo, Licitra Lisa, Canevari Silvana, Locati Laura D, Pilotti Silvana, Perrone Federica, Marchesi Edoardo, Paoli Alessandro, Tonella Luca, Giannoccaro Marco, Sponghini Andrea P, Cossu Rocca Maria, Bergamini Cristiana, Siano Marco, De Cecco Loris
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard
Mottet N, van den Bergh R, Rouvière O, van der Poel H, Lam T, Grummet J, Gillessen Sommer S, Bourke L, Briers E, De Santis M, Cornford P. Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol 2017
02.11.2017Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard
02.11.2017Eur Urol 2017
Mottet Nicolas, van den Bergh Roderick C N, Rouvière Olivier, van der Poel Henk G, Lam Thomas B, Grummet Jeremy P, Gillessen Sommer Silke, Bourke Liam, Briers Erik, De Santis Maria, Cornford Philip
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
De Gregorio A, Janni W, Fasching P, Taran F, Hartkopf A, Jaeger B, Meier-Stiegen F, Pantel K, Schneeweiss A, Mueller V, Riethdorf S, Alunni-Fabbroni M, Trapp E, Rack B, De Gregorio N, Scholz C, Huober J, Friedl T, Fehm T. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol 2017; 1:1-12.
01.11.2017Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
01.11.2017JCO Precis Oncol 2017; 1:1-12
De Gregorio Amelie, Janni Wolfgang, Fasching Peter A, Taran Florin-Andrei, Hartkopf Andreas, Jaeger Bernadette, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Mueller Volkmar, Riethdorf Sabine, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, De Gregorio Nikolaus, Scholz Christoph, Huober Jens, Friedl Thomas W P, Fehm Tanja
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
26.10.2017Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
26.10.2017Breast 2017; 37:42-51
Hartkopf Andreas D, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Fersis Nikos, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Huober Jens, Volz Bernhard, Nabieva Naiba, Taran Florin-Andrei, Schwitulla Judith, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Lux Michael P, Luftner Diana, Wallwiener Markus, Schneeweiss Andreas
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona
Baraniskin A, Seufferlein T, van Cutsem E, Carneiro F, Ducreux M, Gruenberger T, Matysiak-Budnik T, Wasan H, Gueller U, Wyrwicz L, van Laethem J, Schmiegel W. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. Eur J Cancer 2017; 86:305-317.
21.10.2017Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona
21.10.2017Eur J Cancer 2017; 86:305-317
Baraniskin Alexander, Seufferlein Thomas, van Cutsem Eric, Carneiro Fatima, Ducreux Michel, Gruenberger Thomas, Matysiak-Budnik Tamara, Wasan Harpreet S, Gueller Ulrich, Wyrwicz Lucjan, van Laethem Jean-Luc, Schmiegel Wolff
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
20.10.2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
20.10.2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
Scotch A, Kosiorek H, Scherber R, Dueck A, Slot S, Zweegman S, Boekhorst P, Commandeur S, Schouten H, Sackmann F, Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Paoli C, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian J, Zhang P, Gale R, Mesa R, Geyer H. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res 2017; 63:34-40.
14.10.2017Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
14.10.2017Leuk Res 2017; 63:34-40
Scotch Allison H, Kosiorek Heidi, Scherber Robyn, Dueck Amylou C, Slot Stefanie, Zweegman Sonja, Boekhorst Peter A W Te, Commandeur Suzan, Schouten Harry, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Döhner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L, Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M, Paoli Chiara, Passamonti Francesco, Andreasson Bjorn, Ferrari Maria L, Rambaldi Alessandro, Samuelsson Jan, Birgegard Gunnar, Xiao Zhijian, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Kiladjian Jean-Jacques, Zhang Peihong, Gale Robert Peter, Mesa Ruben A, Geyer Holly L
Heart rate variability decreases after 3 months of sustained treatment with fingolimod
Vehoff J, Haegele-Link S, Humm A, Mueller S, Sauter R, Tettenborn B, Hundsberger T. Heart rate variability decreases after 3 months of sustained treatment with fingolimod. J Neurol 2017; 264:2313-2317.
09.10.2017Heart rate variability decreases after 3 months of sustained treatment with fingolimod
09.10.2017J Neurol 2017; 264:2313-2317
Vehoff Jochen, Haegele-Link Stefan, Humm Andrea, Mueller Stefanie Karin, Sauter Rafael, Tettenborn Barbara, Hundsberger Thomas
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz M, Bourayou N, Smith I, Barriga S, Frenzel M, Forrester T, Garnica Jaliffe G, Freedman O, Manso L, Chen S, Trédan O, Park I, Huober J, Paluch-Shimon S, Sohn J, Campone M, Toi M, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35:3638-3646.
02.10.2017MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
02.10.2017J Clin Oncol 2017; 35:3638-3646
Goetz Matthew P, Bourayou Nawel, Smith Ian C, Barriga Susana, Frenzel Martin, Forrester Tammy, Garnica Jaliffe Georgina, Freedman Orit C, Manso Luis, Chen Shin-Cheh, Trédan Olivier, Park In Hae, Huober Jens, Paluch-Shimon Shani, Sohn Joohyuk, Campone Mario, Toi Masakazu, Di Leo Angelo
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Hahnen E, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Neidhardt G, Schem C, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schmutzler R. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3:1378-1385.
01.10.2017Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
01.10.2017JAMA Oncol 2017; 3:1378-1385
Hahnen Eric, Huober Jens, Rhiem Kerstin, Costa Serban, Altmüller Janine, Hanusch Claus, Thiele Holger, Müller Volkmar, Nürnberg Peter, Karn Thomas, Nekljudova Valentina, Untch Michael, von Minckwitz Gunter, Neidhardt Guido, Schem Christian, Lederer Bianca, Hauke Jan, Loibl Sibylle, Kröber Sandra, Schneeweiss Andreas, Denkert Carsten, Fasching Peter A, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Kümmel Sherko, Schmutzler Rita K
Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol 2017
25.09.2017Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
25.09.2017Ann Oncol 2017
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson Per, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Bonnefoi H, Curigliano G
Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.
Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel D, Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. J Oral Maxillofac Surg 2017; 76:775-784.
21.09.2017Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.
21.09.2017J Oral Maxillofac Surg 2017; 76:775-784
Bredell Marius, Rordorf Tamara, Kroiss Sabine, Rücker Martin, Zweifel Daniel Fritz, Rostetter Claudio